Cargando…
Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome
Haemolytic–uraemic syndrome is a clinical syndrome characterized by thrombocytopaenia, non-autoimmune haemolytic anaemia and renal impairment. Pathological alterations in kidney samples show thrombotic microangiopathy. The underlying pathogenesis is endothelial cell injury with thrombotic occlusion...
Autores principales: | Durán, Carlos E., Blasco, Miquel, Maduell, Francisco, Campistol, Josep M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400444/ https://www.ncbi.nlm.nih.gov/pubmed/26069742 http://dx.doi.org/10.1093/ndtplus/sfr107 |
Ejemplares similares
-
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis
por: Kim, Jon Jin, et al.
Publicado: (2012) -
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
por: Macia, Manuel, et al.
Publicado: (2017) -
Outcome of atypical haemolytic uraemic syndrome relapse after
eculizumab withdrawal
por: Duineveld, Caroline, et al.
Publicado: (2020)